{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-129004","form_type":"8-K","ticker":"CVRX","cik":"0001235912","company_name":"CVRx, Inc.","filed_at":"2023-12-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.469108+00:00","generated_at":"2026-06-07T07:14:08.667510+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"CVRx receives FDA approval for expanded Barostim labeling; annual market opportunity increases to $2.2B","bullets":["FDA approved revised Instructions For Use for Barostim incorporating long-term BeAT-HF trial data (NYHA Class III/II, EF ≤35%, NT-proBNP <1600 pg/ml).","Clinical Summary includes 6/12/24-month data, win ratio, all-cause mortality; primary safety endpoint met, but CV death+HF hospitalization endpoint not met.","U.S. annual market opportunity revised to $2.2B (76,000 new patients) from $1.4B (55,000), increases of ~60% and 38%.","CEO Nadim Yared highlighted validation of long-term results and ability to share data with physicians and patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-129004","json":"https://secwatch.observer/filing/0001104659-23-129004.json","markdown":"https://secwatch.observer/filing/0001104659-23-129004.md","text":"https://secwatch.observer/filing/0001104659-23-129004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1235912/000110465923129004/0001104659-23-129004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1235912/000110465923129004/tm2333686d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T07:14:08.667510+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}